Press releases and articles

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership ...

Our solutions for maximum blot efficiency!

With the introduction of the EUROMicroblots last year, we miniaturised our successful blot technology to the size of a microplate well to make processing even more efficient and to save resources.

Let’s embark on a new journey together!

Get started with us as a trusted partner on the way to a simple and reliable routine for your allergy diagnostics!
The (ChLIA) journey begins

The new generation of CSF ELISAs

CSF diagnostics means the analysis of the fluid that circulates in the brain and the bone marrow (liquor cerebrospinalis, cerebrospinal fluid). It is a valuable tool to detect acute or chronic ...

Reflecting on a decade of collaborating excellence: 10 years of neurology at Wieslab AB

A decade ago, an excellent collaboration began for the benefit of neurological diagnostics: Wieslab AB is celebrating its 10th anniversary in neurology ‒ together with EUROIMMUN. We wanted to know ...

Updated COVID-19 XBB.1.5 vaccines elicit strong immune responses to new SARS-CoV-2 variants

Two new studies on SARS-CoV-2 vaccine immune responses suggest that the XBB.1.5-containing mRNA vaccines most likely increase protection against COVID-19 caused by currently circulating XBB variants ...

EUROIMMUN’s portfolio for therapeutic drug monitoring is expanding

EUROIMMUN has been offering test systems for therapeutic drug monitoring (TDM) since 2019. Owing to the cooperation with IDS and their range of TDM products from Theradiag, we were able to ...

Immunoblots: an old friend with a new face – An interview with EUROIMMUN

Ultrafast immunofluorescence microscopy – now with 89 new products for autoimmune and infection diagnostics

First newly developed ELISA of risk class B declared IVDR-compliant

After EUROIMMUN received the required certificate for its quality management system in accordance with the new European Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) in May of ...

Back to top